Cargando…
Leflunomide as a Corticosteroid-Sparing Agent in Giant Cell Arteritis and Polymyalgia Rheumatica: A Case Series
Objectives. Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) affect individuals older than 50 years of age and corticosteroids are the mainstay of treatment. The aim of our study was to explore the role of leflunomide as a corticosteroid-sparing agent in GCA and PMR patients. Methods. Pat...
Autores principales: | Diamantopoulos, Andreas P., Hetland, Helene, Myklebust, Geirmund |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784071/ https://www.ncbi.nlm.nih.gov/pubmed/24106691 http://dx.doi.org/10.1155/2013/120638 |
Ejemplares similares
-
Is Tocilizumab Effective and Safe in Polymyalgia Rheumatica and Giant-Cell Arteritis With Polymyalgia Rheumatica?
por: Farinango, Michelle, et al.
Publicado: (2022) -
Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients
por: Ramon, André, et al.
Publicado: (2022) -
Optimal management of giant cell arteritis and polymyalgia rheumatica
por: Charlton, Rodger
Publicado: (2012) -
Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica
por: Gonzalez-Gay, Miguel A
Publicado: (2001) -
Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update
por: Nesher, Gideon, et al.
Publicado: (2016)